title: NFAT interactions with the vasoactive intestinal peptide cytokine response element.
abstract: The vasoactive intestinal peptide cytokine response element (VIP CyRE) is responsible for mediating the transcriptional induction of the VIP gene to the neuropoietic cytokines leukemia inhibitory factor (LIF) and ciliary neurotrophic factor (CNTF). In investigating the sequence and function of the CyRE, we found a region of DNA with homology to the distal NFAT site in the IL-2 promoter. In this paper we characterize this sequence and show that the VIP NFAT site recognizes T cell NFAT with similar affinity to the previously characterized IL-2 NFAT site. However, despite its location in the middle of the CyRE, we find no CNTF/LIF induced binding to it. Instead we show that in NBFL neuroblastoma cells, the calcium ionophore A23187 induces a protein to bind to the VIP NFAT site. This A23187-mediated induction of nuclear protein binding to an NFAT oligonucleotide is dependent on extracellular calcium but not dependent on de novo protein synthesis. Thus, this protein has the characteristics of an NFAT-like protein and is recognized by an NFAT3-specific antiserum suggesting that it is indeed an NFAT protein. The location of the NFAT site in the VIP CyRE suggests that this may be one mechanism through which different signaling pathways engage in cross talk to alter VIP gene transcription.
authors.affiliation: Massachusetts General Hospital, Department of Neurology, Harvard Medical School, Boston, USA. Symes@bob.usuf2.usuhs.mil
authors.forename: A
authors.initials: A
authors.lastname: Symes
authors.forename: T
authors.initials: T
authors.lastname: Gearan
authors.forename: J S
authors.initials: JS
authors.lastname: Fink
mesh_terms: D000818:Animals; D001483:Base Sequence; D001665:Binding Sites; D000001:Calcimycin / Q000494:pharmacology; D020934:Ciliary Neurotrophic Factor; D016207:Cytokines / Q000494:pharmacology*; D004247:DNA / Q000737:chemistry / Q000378:metabolism; D017931:DNA Primers; D004268:DNA-Binding Proteins / Q000378:metabolism*; D006131:Growth Inhibitors / Q000494:pharmacology*; D006801:Humans; D015850:Interleukin-6; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines / Q000494:pharmacology*; D016297:Mutagenesis, Site-Directed; D050778:NFATC Transcription Factors; D009414:Nerve Growth Factors / Q000494:pharmacology; D009419:Nerve Tissue Proteins / Q000494:pharmacology*; D009447:Neuroblastoma; D009687:Nuclear Proteins; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000494:pharmacology; D012045:Regulatory Sequences, Nucleic Acid; D015398:Signal Transduction; D014157:Transcription Factors / Q000378:metabolism*; D014158:Transcription, Genetic / Q000187:drug effects; D014162:Transfection; D014407:Tumor Cells, Cultured; D014660:Vasoactive Intestinal Peptide / Q000096:biosynthesis* / Q000235:genetics*
chemical_list: D020934:Ciliary Neurotrophic Factor; D016207:Cytokines; D017931:DNA Primers; D004268:DNA-Binding Proteins; D006131:Growth Inhibitors; D015850:Interleukin-6; C507837:LIF protein, human; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines; D050778:NFATC Transcription Factors; D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins; D009687:Nuclear Proteins; D011994:Recombinant Proteins; D014157:Transcription Factors; D014660:Vasoactive Intestinal Peptide; D000001:Calcimycin; D004247:DNA